Skip to main content
Equibles
RIGL logo

RIGL · Rigel Pharmaceuticals Inc · Earnings Call Transcripts & Audio

Track RIGL — free

Use RIGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RIGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$48.25 +0.10 (+0.20%)
Russell 2000 member Rebalance outlook locked
Market Cap
$900.00M
Shares
18.68M
Volume · Oct 1 22.43K Avg daily vol (3M) 308.02K

Rigel Pharmaceuticals Inc Earnings Call Transcripts

Quarterly earnings calls for Rigel Pharmaceuticals Inc (RIGL), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲4% $22.41M −$19.04M '22 Q3 22-11-03 ▲151.3% $51.28M $1.40M '22 Q4 23-03-07 ▲55.8% $26.07M −$13.54M '23 Q1 23-05-02 ▼9.8% $26.89M −$6.60M '23 Q2 23-08-01 ▲25.5% $28.13M −$5.69M '23 Q3 23-11-07 ▼30.2% $35.79M $737,000 '23 Q4 24-01-08 ▲13.3% $29.53M −$8.25M '24 Q1 24-05-07 ▲37% $36.84M −$1.03M '24 Q2 24-08-06 ▲96.6% $55.31M $12.42M '24 Q3 24-11-07 ▲60.9% $57.60M $14.34M '24 Q4 25-03-04 ▲80.6% $53.33M $11.45M '25 Q1 25-05-06 ▲176% $101.69M $59.61M '25 Q2 25-08-05 ▲25.6% $69.46M $27.90M '25 Q3 25-11-04 ▲21.2% $69.80M $268.06M '25 Q4 26-03-03 ▲10.3% $58.82M $8.65M '26 Q1 26-05-05 LATEST ▼22.6% $78.70M $17.29M '26 Q2 26-08-04
Conference
Investor event
2026-09-15
Rigel Pharmaceuticals Inc (RIGL) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-10
Rigel Pharmaceuticals Inc (RIGL) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Capital Markets Day
Investor event
2026-08-13
Rigel Pharmaceuticals Inc (RIGL) August 2026 Capital Markets Day
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Rigel Pharmaceuticals Inc (RIGL) Q2 2026 Earnings Call Transcript
Confident tone Commercial Launch Execution Breast Cancer Market Opportunity Pipeline / R289 Development
Revenue
$78.70M
▼ 22.6% YoY
Diluted EPS
$0.88
▼ 73.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Rigel Pharmaceuticals Inc (RIGL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-12
Rigel Pharmaceuticals Inc (RIGL) May 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Rigel Pharmaceuticals Inc (RIGL) Q1 2026 Earnings Call Transcript
Confident tone R289 pipeline in lower-risk MDS Net product sales growth 2026 financial guidance and profitability
Revenue
$58.82M
▲ 10.3% YoY
Diluted EPS
$0.44
▼ 30.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Transcript
Confident tone R289 pipeline in lower-risk MDS Net product sales growth Commercial product portfolio
Revenue
$69.80M*
▲ 21.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Rigel Pharmaceuticals Inc (RIGL) Q3 2025 Earnings Call Transcript
Confident tone R289 development in lower-risk MDS Olutasidenib pipeline expansion Commercial product sales growth
Revenue
$69.46M
▲ 25.6% YoY
Diluted EPS
$1.46
▲ 108.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Transcript
Revenue
$101.69M
▲ 176% YoY
Diluted EPS
$3.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Call Transcript
Confident tone R289 pipeline in MDS Olutasidenib expansion into glioma Commercial portfolio of three products
Revenue
$53.33M
▲ 80.6% YoY
Diluted EPS
$0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Rigel Pharmaceuticals Inc (RIGL) Q4 2024 Earnings Call Transcript
Confident tone Commercial portfolio growth and product sales Pipeline development - R289 in lower-risk MDS Olutasidenib collaborations and IDH1 mutant cancers
Revenue
$57.60M*
▲ 60.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Transcript
Confident tone Commercial growth and product sales GAVRETO integration and transition Pipeline development and R289
Revenue
$55.31M
▲ 96.6% YoY
Diluted EPS
$0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Rigel Pharmaceuticals Inc (RIGL) Q2 2024 Earnings Call Transcript
Confident tone GAVRETO acquisition and launch R289 pipeline in MDS TAVALISSE commercial performance
Revenue
$36.84M
▲ 37% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript
Confident tone TAVALISSE demand growth REZLIDHIA uptake GAVRETO acquisition
Revenue
$29.53M
▲ 13.3% YoY
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Rigel Pharmaceuticals Inc (RIGL) Q4 2023 Earnings Call Transcript
Confident tone GAVRETO acquisition and commercial opportunity TAVALISSE and REZLIDHIA commercial performance Market expansion via RET testing and biomarker awareness
Revenue
$35.79M*
▼ 30.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Rigel Pharmaceuticals Inc (RIGL) Q3 2023 Earnings Call Transcript
Revenue
$28.13M
▲ 25.5% YoY
Diluted EPS
$-0.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Rigel Pharmaceuticals Inc (RIGL) Q2 2023 Earnings Call Transcript
Revenue
$26.89M
▼ 9.8% YoY
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Rigel Pharmaceuticals Inc (RIGL) Q1 2023 Earnings Call Transcript
Revenue
$26.07M
▲ 55.8% YoY
Diluted EPS
$-0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Rigel Pharmaceuticals Inc (RIGL) Q4 2022 Earnings Call Transcript
Revenue
$51.28M*
▲ 151.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Rigel Pharmaceuticals Inc (RIGL) Q3 2022 Earnings Call Transcript
Revenue
$22.41M
▲ 4% YoY
Diluted EPS
$-1.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Rigel Pharmaceuticals Inc (RIGL) Q2 2022 Earnings Call Transcript
Revenue
$29.82M
▲ 13.5% YoY
Diluted EPS
$-0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Rigel Pharmaceuticals Inc (RIGL) Q1 2022 Earnings Call Transcript
Revenue
$16.73M
▼ 79.3% YoY
Diluted EPS
$-1.60
▼ 172.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Rigel Pharmaceuticals Inc (RIGL) Q4 2021 Earnings Call Transcript
Revenue
$20.41M*
▲ 10.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Rigel Pharmaceuticals Inc (RIGL) Q3 2021 Earnings Call Transcript
Revenue
$21.54M
▲ 17.2% YoY
Diluted EPS
$-1.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Rigel Pharmaceuticals Inc (RIGL) Q2 2021 Earnings Call Transcript
Revenue
$26.27M
▲ 63.9% YoY
Diluted EPS
$-0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Rigel Pharmaceuticals Inc (RIGL) Q1 2021 Earnings Call Transcript
Revenue
$81.02M
▲ 45.3% YoY
Diluted EPS
$2.20
▲ 69.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Rigel Pharmaceuticals Inc (RIGL) Q4 2020 Earnings Call Transcript
Revenue
$18.45M
▲ 19.8% YoY
Gross margin
94.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Rigel Pharmaceuticals Inc (RIGL) Q3 2020 Earnings Call Transcript
Revenue
$18.39M
▼ 11.8% YoY
Diluted EPS
$-0.80
Gross margin
87.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Rigel Pharmaceuticals Inc (RIGL) Q2 2020 Earnings Call Transcript
Revenue
$16.02M
▲ 53.9% YoY
Diluted EPS
$-1.00
Gross margin
91.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Rigel Pharmaceuticals Inc (RIGL) Q1 2020 Earnings Call Transcript
Revenue
$55.76M
▲ 341.7% YoY
Diluted EPS
$1.30
Gross margin
22.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Rigel Pharmaceuticals Inc (RIGL) Q4 2019 Earnings Call
Revenue
$15.40M
▼ 59.3% YoY
Gross margin
88.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–32 of 32 earnings calls
Key facts CIK 1034842 CUSIP 766559702 13F (30d) 2 filings 2 filers Visit website Investor relations